ClinicalTrials.gg
Drug

Mapracorat clinical trials

Also written BOL-303242-X and ZK 245186.

studies test it
13
open now
0
in phase 3
4
first study started
2009

How each study uses mapracorat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Mapracorat
10

Development codes

BOL-303242-X
3
ZK 245186
2

Studies by the year they started

13 studies that test it; most in 2011 (5)

Studies that test mapracorat, by start year
YearStudies
20092
20102
20115
20122
20132

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
7
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 13 · Other 0

Bausch & Lomb Incorporated (7) · Bayer (6)

Studies

Open first, then newest update. How each study uses mapracorat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 13

Codes

What other systems call mapracorat · ClinicalTrials.gg INT005556

  • UNII (FDA) 145V79YBVPMAPRACORATConfirmed FDA, Wikidata
  • Wikidata Q6754194mapracoratConfirmed FDA, Wikidata
  • NCI Thesaurus C166458MapracoratOne source FDA
  • DrugBank DB12041One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.